Table 2.
Medication | Target | Indication | Phase | Trial identifier |
---|---|---|---|---|
Guselkumab | IL-23 | Lupus nephritis | Phase 1/2 | NCT04376827 |
Ustekinumab | IL-12 and IL-23 | Systemic lupus erythematosus | Phase 3 | NCT04060888 |
Secukinumab | IL-17A | Lupus nephritis | Phase 3 | NCT04181762 |
Discoid lupus erythematosus | Phase 2 | NCT03866317 | ||
PF-06835375 | TYK2 | Systemic lupus erythematosus | Phase 1 | NCT03334851 |
Baricitinib | JAK 1 and JAK2 | Systemic lupus erythematosus | Phase 3 | NCT03843125 |